News

MEDIROM Healthcare Technologies Inc. Announces New JPY350 Million (Approximately $2.4 Million*) Unsecured Loan Financing

TOKYO, March 17, 2025 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (Nasdaq CM: MRM), a holistic healthcare company based in Japan (the “Company” or “MEDIROM”), today announced that it has obtained a new unsecured short-term bank loan in the amount of JPY350 million (approximately $2.4 million*). The Company has used JPY200 million of the loan funds for repayment of indebtedness of MEDIROM Mother Labs Inc., a subsidiary of the Company which is also a guarantor of the new loan, and the Company intends to use the remainder of the loan funds for general working capital, including Mother Bracelet development. The loan bears interest at a rate of 1.875% per year.

03/17/2025

MEDIROM Mother Labs Executive Makes Additional Investment in Mother Labs' Series A Financing at a Pre-Money Valuation of JPY9 Billion (as of March 13, 2025, Approximately US$60 Million)

TOKYO, March 13, 2025 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) (the “Company” or “MEDIROM”) announces that Yasuhiro Hayami, Chief Business Officer of MEDIROM Mother Labs Inc. (“Mother Labs”), a subsidiary of the Company, has made a second investment in Mother Labs' Series A financing at a pre-money valuation of JPY9 billion (as of March 13, 2025, approximately US$60 million). This new investment follows Mr. Hayami's initial investment in the Series A financing in December 2024. Mr. Hayami is a committed senior executive of Mother Labs and shares MEDIROM's corporate philosophy and vision as well as commitment to future growth potential.

03/13/2025

Profitability

Gross Profit Margin	20.77 %
Net Income Per EBT	52.49 %
Net Profit Margin	-1.58 %
Return on Assets	-1.92 %
Return on Equity	146.68 %

Dividends

Dividend Yield (FWD)	Nil
Dividend Per Share	Nil
Payout Ratio	Nil
Payout Date	Nil
Ex-Dividend Date	Nil
Latest Announced Dividend	Nil

Income Statement

Revenue	$6.83B
Gross Profit	$1.57B
Gross Profit Ratio	23%
EBITDA	$0.31B
Net Income	$0.12B
EPS Diluted	22.27

Balance Sheet

Long Term Debt	$2.39B
Total Liabilities	$6.63B
Total Equity	$0.22B
Total Investments	$0.08B
Total Debt	$3.65B
Total Assets	$6.85B

Cash Flow Statement

Net Income	$0.12B
Inventory	$-0.03B
Dividends Paid	$0B
Operating Cash Flow	$-0.63B
Capital Expenditure	$-0.14B

Symbol Frequently Asked Questions

Is MEDIROM Healthcare Technologies Inc. (MRM) a buy, sell, or hold?

MEDIROM Healthcare Technologies Inc. (MRM) can sell. Click on Rating Page for detail.

What is MEDIROM Healthcare Technologies Inc.'s stock price?

The price of MEDIROM Healthcare Technologies Inc. (MRM) is 0.6947 and it was updated on 2025-04-04 01:12:01.

Is MEDIROM Healthcare Technologies Inc. (MRM) overvalued or undervalued?

Currently MEDIROM Healthcare Technologies Inc. (MRM) is in undervalued.

News

From:

To:

Show entries

Search:

News
MEDIROM Healthcare Technologies Inc. Announces December 2024 Key Performance Indicators (KPIs) Total Customers Served: 80,764 – Sales Per Customer: JPY 7,384 – Customer Repeat Ratio: 77.6% Total Customers Served: 80,764 – Sales Per Customer: JPY 7,384 – Customer Repeat Ratio: 77.6% Wed, Jan. 29, 2025
MEDIROM MOTHER Labs Provides MOTHER Bracelet®︎ Device and Remote Health Monitoring System, REMONY, to TOPPAN Inc. TOKYO, Jan. 21, 2025 (GLOBE NEWSWIRE) -- MEDIROM Healthcare technologies Inc. (NASDAQ: MRM) (“MEDIROM”), a health technology and holistic healthcare company headquartered in Tokyo, Japan and led by CEO Kouji Eguchi, is pleased to announce that its subsidiary, MEDIROM MOTHER Labs Inc. (“MOTHER Labs”) is now providing its remote health monitoring system, REMONY, and charging-free smart tracker device, MOTHER Bracelet®︎, to the Electronics Division of TOPPAN Inc. (Tokyo Stock Exchange: 7911). Tue, Jan. 21, 2025
MEDIROM Healthcare Technologies Inc. Announces November 2024 Key Performance Indicators (KPIs) Total Customers Served: 75,760 – Sales Per Customer: JPY 7,055 – Customer Repeat Ratio: 77.5% Total Customers Served: 75,760 – Sales Per Customer: JPY 7,055 – Customer Repeat Ratio: 77.5% Mon, Dec. 23, 2024
MEDIROM Healthcare Technology‘s Subsidiary, MEDIROM MOTHER Labs, Raises an Aggregate Total of JPY260.3 Million in its Series A Financing Round TOKYO, Dec. 13, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) announces that its subsidiary MEDIROM MOTHER Labs Inc. raised to date an aggregate total of 260.3 million yen (approximtaely USD $ [1.7] million calculated at an exchange rate of JPY[153.64] to US$1) at a pre-money equity valuation of JPY9 billion (approximately USD $ [58.6] million calculated at an exchange rate of JPY[153.64] to US$1) in its Series A equity financing. NFES Technologies Inc. is the lead investor in the financing round, and several public companies in Japan, including M3, Inc. (TOKYO PRIME: 2413) and Elematec Corporation (TOKYO PRIME: 2715), as well as certain individual investors are also participating. The Series A equity financing round is still ongoing. MEDIROM MOTHER Labs has closed financings with six investors to date and intends to conclude the financing round by December 31, 2024. “We are very excited that our MEDIROM MOTHER Labs subsidiary has received such significant validation from strategic partners as our lead investor NFES Technologies Inc. as well as M3,Inc and Elematec Corporation. The pre money valuation of 9 billion yen is approximately multiples of MEDIROM's current NASDAQ listing market capitalization which I believe further validates our technology, business model and growth potential.” said Kouji. Fri, Dec. 13, 2024
MEDIROM Healthcare Technologies Inc. Announces Closing of Public Offering TOKYO, Dec. 11, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM), “MEDIROM”, a holistic healthcare company that operates over 300 wellness salons across Japan and provides healthcare services, today announced the closing of its public offering of 2,860,000 American Depositary Shares at a public offering price of $1.75 per share, for gross proceeds of approximately $5,000,000 before deducting underwriting discounts and offering expenses. In addition, MEDIROM has granted the underwriters a 45-day option to purchase up to an additional 429,000 American Depositary Shares to cover over-allotments at the public offering price, less the underwriting discount. Wed, Dec. 11, 2024

Showing 1 to 5 of 5 entries

Previous1Next

SEC Filings

Show entries

Search:

SEC Filings
MEDIROM Healthcare Technologies Inc. (MRM) - 6-K - Current report SEC Filings 03/21/2025
MEDIROM Healthcare Technologies Inc. (MRM) - 6-K - Current report SEC Filings 03/17/2025
MEDIROM Healthcare Technologies Inc. (MRM) - 6-K - Current report SEC Filings 03/13/2025
MEDIROM Healthcare Technologies Inc. (MRM) - 6-K - Current report SEC Filings 03/04/2025
MEDIROM Healthcare Technologies Inc. (MRM) - 6-K - Current report SEC Filings 02/21/2025
MEDIROM Healthcare Technologies Inc. (MRM) - 6-K - Current report SEC Filings 02/18/2025
MEDIROM Healthcare Technologies Inc. (MRM) - 6-K - Current report SEC Filings 01/29/2025
MEDIROM Healthcare Technologies Inc. (MRM) - 6-K - Current report SEC Filings 01/21/2025
MEDIROM Healthcare Technologies Inc. (MRM) - 6-K - Current report SEC Filings 12/27/2024
MEDIROM Healthcare Technologies Inc. (MRM) - 6-K - Current report SEC Filings 12/23/2024

Showing 1 to 10 of 155 entries

Previous1 2 3 4 5…16Next

Press Releases

Show entries

Search:

StockPrice Release
Medirom healthcare technologies inc. announces new jpy350 million (approximately $2.4 million*) unsecured loan financing 03/17/2025
Medirom mother labs executive makes additional investment in mother labs' series a financing at a pre-money valuation of jpy9 billion (as of march 13, 2025, approximately us$60 million) 03/13/2025
Medirom healthcare technologies inc. announces december 2024 key performance indicators (kpis) 01/29/2025
Medirom mother labs provides mother bracelet®︎ device and remote health monitoring system, remony, to toppan inc. 01/21/2025
Medirom healthcare technologies inc. announces november 2024 key performance indicators (kpis) 12/23/2024
Medirom healthcare technology‘s subsidiary, medirom mother labs, raises an aggregate total of jpy260.3 million in its series a financing round 12/13/2024
Medirom healthcare technologies inc. announces closing of public offering 12/11/2024
Two senior medirom mother labs executives invest in mother labs' series a financing at a pre-money valuation of jpy9 billion (as of december 1, 2024, approximately usd $59,000,000) 12/11/2024
Medirom healthcare technologies inc. announces pricing of public offering 12/09/2024
Update: medirom healthcare technologies has received orders for over 25,000 mother bracelet units 12/09/2024

Showing 1 to 10 of 60 entries

Previous1 2 3 4 5 6Next

More Headlines

Show entries

Search:

News
Two Senior MEDIROM Mother Labs Executives Invest in Mother Labs' Series A Financing at a Pre-Money Valuation of JPY9 Billion (as of December 1, 2024, approximately USD $59,000,000) TOKYO, Dec. 11, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) (the “Company” or “MEDIROM”) announces that two senior executives, Issei Homan, Chief Technology Officer of MEDIROM MOTHER Labs Inc. (“Mother Labs”), a subsidiary of MEDIROM, and Yasuhiro Hayami, Chief Business Officer of Mother Labs, invested in Mother Labs' Series A financing at a pre-money valuation of of JPY9 billion (as of December 1, 2024, approximately USD $59,000,000). Messrs. Homan and Hayami are committed senior executives of Mother Labs and share MEDIROM's corporate philosophy and vision as well as commitment to future growth potential. 12/11/2024
MEDIROM Healthcare Technologies Inc. Announces Pricing of Public Offering TOKYO, Dec. 09, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM), “MEDIROM”, a holistic healthcare company that operates over 300 wellness salons across Japan and provides healthcare services, today announced the pricing of a public offering of 2,860,000 American Depositary Shares at a public offering price of $1.75 per share, for gross proceeds of approximately $5,000,000, before deducting underwriting discounts and offering expenses. In addition, MEDIROM has granted the underwriters a 45-day option to purchase up to an additional 429,000 American Depositary Shares to cover over-allotments at the public offering price, less the underwriting discount. The Offering is expected to close on December 11, 2024, subject to the satisfaction of customary closing conditions. 12/09/2024
UPDATE: MEDIROM Healthcare Technologies Has Received Orders for Over 25,000 MOTHER Bracelet Units TOKYO, Dec. 09, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) (“MEDIROM”) announces that its subsidiary MEDIROM MOTHER Labs Inc. has received orders for over 25,000 MOTHER Bracelet units, including orders from Japanese companies such as NFES Technologies Inc. 12/09/2024
MEDIROM Healthcare Technologies Has Received Orders for Over 25,000 MOTHER Bracelet Units TOKYO, Dec. 09, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) (“MEDIROM”) announces that its subsidiary MEDIROM MOTHER Labs Inc. has received orders for over 25,000 MOTHER Bracelet units, including orders from Japanese companies such as NFES Technologies Inc. 12/09/2024
M3 Group Joins MEDIROM Mother Labs' Series A Financing Round at JPY9 Billion (as of December 1, 2024, approximately USD $59,000,000) Pre-Money Valuation TOKYO, Dec. 06, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) (“MEDIROM”) announces that M3, Inc. (TOKYO PRIME: 2413), or an affiliate within the M3 group, is participating in the Series A equity financing round of MEDIROM MOTHER Labs Inc., a subsidiary of MEDIROM. NFES Technologies Inc. is the lead investor of the Series A financing round at a pre-money valuation of JPY9 billion. Additional information is available here: https://medirom.co.jp/en/ir/20240824/6148%09 12/06/2024
M3 Group Joins MEDIROM Mother Labs' Series A Financing Round at JPY9 Billion (as of December 1, 2024, approximately USD $59,000,000) Pre-Money Valuation TOKYO, Dec. 02, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) (“MEDIROM”) announces that M3, Inc. (TOKYO PRIME: 2413), or an affiliate within the M3 group, is participating in the Series A equity financing round of MEDIROM MOTHER Labs Inc., a subsidiary of MEDIROM. NFES Technologies Inc. is the lead investor of the Series A financing round at a pre-money valuation of JPY9 billion. Additional information is available here: https://medirom.co.jp/en/ir/20240824/6148%09 12/02/2024
SBC Medical Group Holdings and MEDIROM Healthcare Technologies Announce Business Alliance TOKYO--(BUSINESS WIRE)-- #InvestorRelations--SBC Medical Group Holdings Incorporated (Nasdaq: SBC) , announced a business alliance with MEDIROM Healthcare Technologies Inc.(Nasdaq: MRM) . 11/07/2024
MEDIROM Rehab Solutions Inc. Acquires Rehabilitation Centers from Y's, Inc. TOKYO, Oct. 07, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) (“Medirom” or the “Company”) is pleased to announce that it is capitalizing on its extensive experience operating wellness clinics and healthcare technology to expand into the rehabilitation industry. In doing so, MEDIROM established a wholly-owned subsidiary, MEDIROM Rehab Solutions Inc., which acquired all of the rehabilitation centers of Y's, Inc. Prior to the acquisition by MEDIROM Rehab Solutions Inc., Y's, Inc. owned and operated ten cerebral infarction rehabilitation centers in Tokyo and other major cities across Japan. 10/07/2024
Capital and Business Alliance Formed Between MEDIROM MOTHER Labs and NFES Technologies NFES Group Selected as Lead Investor in Series A Round Valued at 9 Billion Yen NFES Group Selected as Lead Investor in Series A Round Valued at 9 Billion Yen 08/23/2024
MEDIROM Healthcare Technologies Announces Business Transfer from Y's, Inc. TOKYO, July 22, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (“we”, “our”, “us” or “the Company”) hereby announces that its subsidiary MEDIROM Rehab Solutions Inc. entered into an agreement to purchase a rehabilitation business from Y's, Inc., a Japanese corporation, as of July 10, 2024. 07/22/2024

Showing 1 to 10 of 37 entries

Previous1 2 3 4Next

Unlock

MRM Ratings Summary

Quant

Sell

MRM Quant Ranking

Sector	Consumer Cyclical
Industry	Personal Products & Services
Quant Rating	Sell
Quant Score	2

Is MEDIROM Healthcare Technologies Inc. (MRM) a buy, sell, or hold?

What is MEDIROM Healthcare Technologies Inc.'s stock price?

Is MEDIROM Healthcare Technologies Inc. (MRM) overvalued or undervalued?

Two Senior MEDIROM Mother Labs Executives Invest in Mother Labs' Series A Financing at a Pre-Money Valuation of JPY9 Billion (as of December 1, 2024, approximately USD $59,000,000)

MEDIROM Healthcare Technologies Inc. Announces Pricing of Public Offering

UPDATE: MEDIROM Healthcare Technologies Has Received Orders for Over 25,000 MOTHER Bracelet Units

MEDIROM Healthcare Technologies Has Received Orders for Over 25,000 MOTHER Bracelet Units

M3 Group Joins MEDIROM Mother Labs' Series A Financing Round at JPY9 Billion (as of December 1, 2024, approximately USD $59,000,000) Pre-Money Valuation

M3 Group Joins MEDIROM Mother Labs' Series A Financing Round at JPY9 Billion (as of December 1, 2024, approximately USD $59,000,000) Pre-Money Valuation

SBC Medical Group Holdings and MEDIROM Healthcare Technologies Announce Business Alliance

MEDIROM Rehab Solutions Inc. Acquires Rehabilitation Centers from Y's, Inc.

Capital and Business Alliance Formed Between MEDIROM MOTHER Labs and NFES Technologies

MEDIROM Healthcare Technologies Announces Business Transfer from Y's, Inc.

Company Details

Ratings

Quant Factor Grades

Trading

Dividend Grades

Dividend

Earnings

Valuation

Growth

Performance

Momentum

Profitability

Risk

Ownership

Debt